Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in R&D and commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.
Latest from Dexter Jie Yan
In the head-to-head Phase III HARMONY trial in metformin-failed type 2 diabetes, HighTide's HTD1801 yielded a mean 1.12% reduction in HbA1c from baseline at 24 weeks, versus 0.93% for AstraZeneca’s Farxiga.
Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.
Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.
In a world-first, Beijing Mabworks has scored a Phase III clinical win for its novel anti-CD20 antibody in the treatment of primary membranous nephropathy. However, multiple global contenders including Roche are threatening to come from behind in the race.
Newly revealed data on HLX43’s recommended Phase II/III dose has boosted Henlius’s confidence to launch up to eight Phase III trials of the ADC in lung cancer. Phase III trials of the agent in more cancer types are also on the horizon.
On the back of long-term durability data expected from a Phase II study in the fourth quarter, NovaBridge plans to advance VIS-101 into a Phase III head-to-head trial against Roche’s Vabysmo.